Design and evaluation of nitrosylated α-adrenergic receptor antagonists as potential agents for the treatment of impotence

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 121-128

  Sáenz De Tejada, Iñigo ^a,c   Garvey, D S ^b   Schroeder, J D ^b   Shelekhin, T ^b   Letts, L G ^b   Fernandez A ^a   Cuevas, B ^a   Gabancho, S ^a   Martinez V ^a   Angulo, J ^a   Trocha, M ^b   Marek, P ^b   Cuevas, P ^a   Tam, S W ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NitroMed Inc   (United States)

^c Fondacion Invest Desarrollo A   (Spain)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; MOXISYLYTE; NITRIC OXIDE DONOR; NMI 187; NMI 221; UNCLASSIFIED DRUG; YOHIMBINE; YOHIMBINE DERIVATIVE; ZAPRINAST;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; IMPOTENCE; IN VITRO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CYCLIC GMP; DRUG DESIGN; ENDOTHELINS; HUMANS; IMPOTENCE; MALE; MEMBRANES; MICE; MOXISYLYTE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITROSO COMPOUNDS; PENIS; PHENYLEPHRINE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; VASODILATOR AGENTS; YOHIMBINE;

EID: 0345711609     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Azadzoi KM, Kim N, Brown ML, Goldstein I, Cohen RA and Sáenz de Tejada I (1992) Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 147:220-225.
2. 2-Adrenoceptor subtypes and imidazoline-like binding sites in the rat brain. Br J Pharmacol 99:803-809.
3. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS and Snyder SH (1992) Nitric oxide: A physiologic mediator of penile erection. Science (Wash DC) 267:401-403.
4. Burnett AL, Tillman SL, Chang TS, Epstein JL, Lowenstein CJ, Bredt DS, Snyder SH and Walsh PC (1993) Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol 150:73-76.
5. 1-adrenoceptor subtypes. Br J Pharmacol 117:703-711.
6. 1. Int J Impotence Res 8:41-46.
7. Carter AJ, Ballard SA and Naylor AM (1998) Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog. J Urol 180:242-246.
8. Clark JT, Smith ER and Davidson JM (1984) Enhancement of sexual motivation in male rats by yohimbine. Science (Wash DC) 225:847-849.
9. Costa P, Bressolle F, Sarrazin B, Mosser J, Navratil H and Galtier M (1992) Moxisylyte plasma kinetics in humans after intracavernous administration. Biopharm Drug Dispos 13:671-679.
10. 1. J Urol 146:786-789.
11. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD and Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med 338:1397-1404.
12. Govier FE, McClure RD, Weissman RM, Gibbons RP, Prichett TR and Kramer-Levien D (1993) Experience with triple-drug therapy in a pharmacological erection program. J Urol 150:1822-1824.
13. 2 and the inhibition of this actions. Pol J Pharmacol Pharm 27:257-264
14. G-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Actaa Physiol Scand 143:299-304.
15. Juneman KP (1996) Anatomy of the penis and elementary physiology of erection, in Penile Disorders (Porst H ed) pp 1-12, Springer-Verlag, New York.
16. Kim N, Azadzoi KM, Goldstein I and Sáenz de Tejada I (1991) A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 88:112-118.
17. Kunelius P, Hakkinen J and Lukkarinen O (1997) Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology 49:441-444.
18. Linet OI and Ogring FG (1996) Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 334:873-877.
19. Munson PJ and Rodbard D (1980) LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
20. Reid K, Surridge DH, Morales A and Fenemore J (1987) Double blind trial of yohimbine in the treatment of psychogenic impotence. Lancet 2:421-422.
21. Sáenz de Tejada I, Kim N, Lagan I, Krane RJ and Goldstein I (1989) Regulation of adrenergic activity in penile corpus cavernosum. J Urol 142:1117-1121.
22. Sáenz de Tejada I, Moroukian P, Tessier J, Kim JJ, Goldstein I and Frohrib D (1991) Trabecular smooth muscle modulates the capacitor function of the penis: Studies on a rabbit model. Am J Physiol 260:H1590-H1595.
23. Shahid M, van Amsterdam RG, de Boer J, ten Berge RE, Nicholson CD and Zaagsma J (1991) The presence of five cyclic nucleotidephosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors. Br J Pharmacol 104:471-477.
24. Simonsen U, Prieto D, Hernández M, Sáenz de Tejada I and García-Sacristán A (1997a) Adrenoceptor-mediated regulation of the contractility in horse penile resistance arteries. J Vasc Res 34:90-102.
25. 2 adrenoceptors inhibit nitrergic neurotransmission in horse penile resistance arteries. J Urol 157:2356-2360.
26. Taher A, Meyer M, Stief CG, Jonas U and Forssmann WG (1997) Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 15:32-35.
27. Tallarida RJ and Murray RB (1987) Manual of Pharmacologie Calculations with Computer Programs. Springer-Verlag, New York.
28. Teloken C, Rhoden EL, Sogari P, Dambros M and Souto CA (1998) Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 159:122-124.
29. 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol 153:222-227.
30. Vaccarino AL, Marek P, Kest B, Weber E, Keana JFW and Liebeskind JC (1993) NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res 615:331-334.